Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.75	$2.27	$1.11 ▼ $5.00	$465.75M	1.9	2.78 million shs	1.35 million shs
PFSCF ProMetic Life Sciences	$5.47	$5.47	$5.47 ▼ $352.00	$127.45M	2.46	279 shs	N/A
PRME Prime Medicine	$3.55 +10.2%	$3.50	$1.11 ▼ $5.17	$477.74M	2.39	2.53 million shs	3.10 million shs
PVLA Palvella Therapeutics	$53.42 +4.1%	$32.98	$11.17 ▼ $53.93	$590.83M	-0.01	156,619 shs	161,988 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	-1.69%	-33.71%	+13.64%	-57.11%
PFSCF ProMetic Life Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
PRME Prime Medicine	0.00%	-0.56%	-18.39%	+175.19%	-19.32%
PVLA Palvella Therapeutics	0.00%	+12.94%	+38.29%	+125.21%	+5,341,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.9319 of 5 stars	3.5	1.0	0.0	0.0	3.3	3.3	0.6
PFSCF ProMetic Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	2.7246 of 5 stars	3.4	1.0	0.0	0.0	1.3	5.0	0.6
PVLA Palvella Therapeutics	1.9634 of 5 stars	2.5	0.0	0.0	0.0	3.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.12	421.14% Upside
PFSCF ProMetic Life Sciences	0.00	N/A	N/A	N/A
PRME Prime Medicine	2.75	Moderate Buy	$8.92	151.17% Upside
PVLA Palvella Therapeutics	3.09	Buy	$58.50	9.51% Upside

Current Analyst Ratings Breakdown

Latest PFSCF, PVLA, AUTL, and PRME Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $66.00
8/15/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $75.00
8/15/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $60.00
8/13/2025	AUTL Autolus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $5.00
8/8/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
8/5/2025	PVLA Palvella Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$54.00
8/4/2025	PVLA Palvella Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$90.00
7/21/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/21/2025	PVLA Palvella Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$56.00
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	46.02	N/A	N/A	$1.30 per share	1.35
PFSCF ProMetic Life Sciences	$36.55M	3.49	N/A	N/A	($67.63) per share	-0.08
PRME Prime Medicine	$4.96M	96.30	N/A	N/A	$1.37 per share	2.59
PVLA Palvella Therapeutics	$42.81M	13.80	N/A	N/A	$4.32 per share	12.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.84	N/A	N/A	N/A	N/A	-56.18%	-29.61%	11/11/2025 (Estimated)
PFSCF ProMetic Life Sciences	-$150.73M	N/A	0.00	∞	N/A	-894.02%	-3,350.55%	-67.76%	N/A
PRME Prime Medicine	-$198.13M	-$1.56	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-62.30%	-43.34%	N/A

Latest PFSCF, PVLA, AUTL, and PRME Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	PVLA Palvella Therapeutics	-$0.78	-$0.86	-$0.08	-$0.86	N/A	N/A
8/12/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.24	-$0.18	+$0.06	-$0.18	$12.92 million	$13.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
PFSCF ProMetic Life Sciences	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	40.73%	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	8.43	8.07
PFSCF ProMetic Life Sciences	N/A	0.95	0.71
PRME Prime Medicine	N/A	6.50	6.50
PVLA Palvella Therapeutics	N/A	7.67	8.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
PFSCF ProMetic Life Sciences	0.10%
PRME Prime Medicine	70.37%
PVLA Palvella Therapeutics	40.11%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
PFSCF ProMetic Life Sciences	N/A
PRME Prime Medicine	22.74%
PVLA Palvella Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
PFSCF ProMetic Life Sciences	50	23.31 million	N/A	Not Optionable
PRME Prime Medicine	234	134.57 million	100.38 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A

PFSCF, PVLA, AUTL, and PRME Headlines

Recent News About These Companies

Institutional investors in Palvella Therapeutics, Inc. (NASDAQ:PVLA) have had a wonderful week after share price increased 13%

August 23 at 3:49 PM | finance.yahoo.com

Palvella Therapeutics (NASDAQ:PVLA) Shares Up 5.7% After Analyst Upgrade

August 22 at 2:01 AM | americanbankingnews.com

Canaccord Genuity Group Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $66.00

August 21 at 10:33 AM | marketbeat.com

Palvella Therapeutics (NASDAQ:PVLA) Reaches New 12-Month High - Here's What Happened

August 21 at 4:47 AM | marketbeat.com

Canaccord Genuity Group Forecasts Strong Price Appreciation for Palvella Therapeutics (NASDAQ:PVLA) Stock

August 21 at 3:01 AM | americanbankingnews.com

Palvella Therapeutics price target raised to $66 from $52 at Canaccord

August 19, 2025 | msn.com

Palvella Therapeutics (NASDAQ:PVLA) Announces Quarterly Earnings Results

August 18, 2025 | marketbeat.com

Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $60.00

August 18, 2025 | americanbankingnews.com

Truist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)

August 17, 2025 | theglobeandmail.com

HC Wainwright Issues Positive Forecast for Palvella Therapeutics (NASDAQ:PVLA) Stock Price

August 17, 2025 | marketbeat.com

Chardan Capital Issues Positive Forecast for Palvella Therapeutics (NASDAQ:PVLA) Stock Price

August 17, 2025 | marketbeat.com

Palvella Therapeutics (NASDAQ:PVLA) Shares Up 3.6% - Time to Buy?

August 16, 2025 | marketbeat.com

Palvella Therapeutics (NASDAQ:PVLA) Reaches New 1-Year High - Still a Buy?

August 15, 2025 | marketbeat.com

Palvella Therapeutics price target raised to $75 from $38 at H.C. Wainwright

August 15, 2025 | msn.com

Palvella Therapeutics price target raised to $60 from $50 at Chardan

August 15, 2025 | msn.com

Palvella Therapeutics price target raised to $60 from $45 at Stifel

August 14, 2025 | msn.com

Palvella Therapeutics reports Q2 EPS (86c), consensus (77c)

August 14, 2025 | msn.com

Palvella Therapeutics: Q2 Earnings Snapshot

August 14, 2025 | timesunion.comT

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025 | globenewswire.com

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

August 7, 2025 | globenewswire.com

Analysts Issue Forecasts for PVLA Q2 Earnings

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSCF, PVLA, AUTL, and PRME Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.75 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.78 +0.02 (+1.43%)

As of 08/22/2025 07:56 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

ProMetic Life Sciences OTCMKTS:PFSCF

$5.47 0.00 (0.00%)

As of 11/18/2019

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Prime Medicine NYSE:PRME

$3.55 +0.33 (+10.25%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.57 +0.02 (+0.56%)

As of 08/22/2025 07:40 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Palvella Therapeutics NASDAQ:PVLA

$53.42 +2.11 (+4.11%)

As of 08/22/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time